Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 11:08

Hutchison's Surufatinib Gets New Drug Application Approval In China

Hutchison's Surufatinib Gets New Drug Application Approval In China

Read more
10 Oct 2019 15:45

Hutchison China Meditech expands collaboration with Innovent

(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..

Read more
10 Oct 2019 12:43

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Read more
4 Oct 2019 15:21

Hutchison Chi-Med initiates latest study of HMPL-523

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.

Read more
4 Oct 2019 10:26

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

Read more
4 Oct 2019 08:39

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Read more
3 Sep 2019 13:25

Hutchison China Starts Trial For HMPL-689 On Lymphoma Treatment

(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at

Read more
23 Aug 2019 11:25

Hutchison China MediTech launches trial for autoimmune disorder treatment

(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

Read more
23 Aug 2019 10:59

Hutchison China Meditech Starts HMPL-523 Trial In China

(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last

Read more
30 Jul 2019 11:43

Hutchison China Interim Loss Widens On Expenses; Alters 2019 Guidance

(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares

Read more
23 Jul 2019 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw

Read more
3 Jul 2019 13:42

Prudential Holds 5% Hutchison China Meditech Stake After Deal

(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in

Read more
28 Jun 2019 16:38

Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing

(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also

Read more
14 Jun 2019 14:40

Hutchison Chi-Med makes progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.

Read more
29 May 2019 12:38

Hutchison China Meditech Shareholders Approve Subdivision Of Shares (ALLISS)

LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.